This company has been marked as potentially delisted and may not be actively trading. Flex Pharma (FLKS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock FLKS vs. OSTX, EGRX, AADI, NBRV, ELYM, HILS, NNVC, IBIO, AEON, and OBSVShould you be buying Flex Pharma stock or one of its competitors? The main competitors of Flex Pharma include OS Therapies (OSTX), Eagle Pharmaceuticals (EGRX), Aadi Bioscience (AADI), Nabriva Therapeutics (NBRV), Eliem Therapeutics (ELYM), Hillstream BioPharma (HILS), NanoViricides (NNVC), iBio (IBIO), AEON Biopharma (AEON), and ObsEva (OBSV). These companies are all part of the "medical" sector. Flex Pharma vs. Its Competitors OS Therapies Eagle Pharmaceuticals Aadi Bioscience Nabriva Therapeutics Eliem Therapeutics Hillstream BioPharma NanoViricides iBio AEON Biopharma ObsEva Flex Pharma (NASDAQ:FLKS) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations. Do institutionals & insiders believe in FLKS or OSTX? 14.4% of Flex Pharma shares are owned by institutional investors. 7.6% of Flex Pharma shares are owned by insiders. Comparatively, 13.8% of OS Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts recommend FLKS or OSTX? OS Therapies has a consensus price target of $18.00, indicating a potential upside of 940.46%. Given OS Therapies' stronger consensus rating and higher probable upside, analysts plainly believe OS Therapies is more favorable than Flex Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flex Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Which has better valuation and earnings, FLKS or OSTX? OS Therapies has lower revenue, but higher earnings than Flex Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFlex Pharma$840K16.16-$21.92MN/AN/AOS TherapiesN/AN/A-$7.79M-$0.86-2.01 Does the media favor FLKS or OSTX? In the previous week, OS Therapies had 3 more articles in the media than Flex Pharma. MarketBeat recorded 3 mentions for OS Therapies and 0 mentions for Flex Pharma. Flex Pharma's average media sentiment score of 0.00 equaled OS Therapies'average media sentiment score. Company Overall Sentiment Flex Pharma Neutral OS Therapies Neutral Is FLKS or OSTX more profitable? OS Therapies has a net margin of 0.00% compared to Flex Pharma's net margin of -1,208.42%. OS Therapies' return on equity of 0.00% beat Flex Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Flex Pharma-1,208.42% -98.04% -83.37% OS Therapies N/A N/A -569.57% SummaryOS Therapies beats Flex Pharma on 9 of the 12 factors compared between the two stocks. Get Flex Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for FLKS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FLKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart FLKS vs. The Competition Export to ExcelMetricFlex PharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.58M$815.41M$5.73B$9.47BDividend YieldN/A4.84%4.60%3.99%P/E RatioN/A1.3827.9319.95Price / Sales16.1626.59438.49101.76Price / CashN/A19.5636.5558.97Price / Book1.476.818.655.90Net Income-$21.92M-$4.28M$3.24B$258.42M Flex Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FLKSFlex PharmaN/A$0.75+7.3%N/A-67.3%$13.58M$840K0.004OSTXOS Therapies2.2044 of 5 stars$1.82+7.7%$18.00+889.0%N/A$51.14MN/A-2.12N/AGap UpEGRXEagle Pharmaceuticals2.5913 of 5 stars$3.69-0.3%N/A-31.4%$47.92M$257.55M0.00100Gap DownAADIAadi Bioscience0.5171 of 5 stars$1.85+2.8%$1.67-9.9%+28.0%$45.69M$25.07M-0.8140NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070ELYMEliem TherapeuticsN/A$1.51+3.4%N/A-82.9%$44.93MN/A-2.859HILSHillstream BioPharmaN/A$1.69+2.4%N/A-47.0%$29.75MN/A-2.351Gap UpNNVCNanoViricides0.4871 of 5 stars$1.70+0.6%N/A-31.3%$27.32MN/A-2.3620IBIOiBio1.3616 of 5 stars$0.74+1.2%$5.00+579.7%-65.8%$12.00M$375K0.00100AEONAEON Biopharma2.7313 of 5 stars$0.80-0.7%$360.00+44,676.1%-99.6%$9.09MN/A4.475OBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050 Related Companies and Tools Related Companies OS Therapies Competitors Eagle Pharmaceuticals Competitors Aadi Bioscience Competitors Nabriva Therapeutics Competitors Eliem Therapeutics Competitors Hillstream BioPharma Competitors NanoViricides Competitors iBio Competitors AEON Biopharma Competitors ObsEva Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FLKS) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flex Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Flex Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
